BioCentury
ARTICLE | Finance

Turbocharging Turnstone

How Turnstone plans to ramp up its clinical programs with $41.4M series B

November 5, 2016 2:27 AM UTC

Turnstone Biologics Inc.’s $41.4 million series B round provides enough runway to ramp up the company’s clinical program and run four Phase I/II trials over the next three years.

OrbiMed Advisors led last week’s tranched round, which saw participation by fellow new investor F-Prime Capital Partners and existing investors Versant Ventures and FACIT. The second and final close is expected next year. ...